GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

Genzyme Gains Marketing Rights for Ceregene’s Parkinson's Drug in $150M Deal

  • Ceregene and Genzyme entered into a partnership for the development and commercialization of Ceregene's Phase II candidate, CERE-120, for the treatment of Parkinson's disease.

    Under the terms of the agreement, Genzyme will pay Ceregene $25 million upfront in exchange for certain partnership-related expenses. Ceregene also is entitled to development-related milestone payments of up to $125 million and 50% reimbursement of the worldwide Phase III development costs.

    Genzyme will gain marketing rights in all areas outside the U.S. and Canada and will pay Ceregene tiered sales royalties.  Ceregene thus retains exclusive rights in the U.S. and Canada.

    “The resources provided by our new partnership with Genzyme, together with the greater than $27-million initial closing of our Series C financing, provides the funding we currently need to advance CERE-120 toward commercialization," points out Jeffrey M. Ostrove, Ph.D., president and CEO of Ceregene.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »